<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">SAGE Open Med Case Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">SAGE Open Med Case Rep</journal-id>
<journal-id journal-id-type="publisher-id">SCO</journal-id>
<journal-id journal-id-type="hwp">spsco</journal-id>
<journal-title-group>
<journal-title>SAGE Open Medical Case Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2050-313X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30377530</article-id>
<article-id pub-id-type="pmc">6202747</article-id>
<article-id pub-id-type="doi">10.1177/2050313X18807622</article-id>
<article-id pub-id-type="publisher-id">10.1177_2050313X18807622</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Successful treatment of choreo-athetotic movements in a patient with
an EEF1A2 gene variant</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-7332-8777</contrib-id>
<name>
<surname>Lance</surname>
<given-names>Eboni I</given-names>
</name>
<xref ref-type="aff" rid="aff1-2050313X18807622">1</xref>
<xref ref-type="aff" rid="aff2-2050313X18807622">2</xref>
<xref ref-type="corresp" rid="corresp1-2050313X18807622"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kronenbuerger</surname>
<given-names>Martin</given-names>
</name>
<xref ref-type="aff" rid="aff2-2050313X18807622">2</xref>
<xref ref-type="aff" rid="aff3-2050313X18807622">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cohen</surname>
<given-names>Julie S</given-names>
</name>
<xref ref-type="aff" rid="aff4-2050313X18807622">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Furmanski</surname>
<given-names>Orion</given-names>
</name>
<xref ref-type="aff" rid="aff5-2050313X18807622">5</xref>
<xref ref-type="aff" rid="aff6-2050313X18807622">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Singer</surname>
<given-names>Harvey S</given-names>
</name>
<xref ref-type="aff" rid="aff2-2050313X18807622">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fatemi</surname>
<given-names>Ali</given-names>
</name>
<xref ref-type="aff" rid="aff2-2050313X18807622">2</xref>
<xref ref-type="aff" rid="aff4-2050313X18807622">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-2050313X18807622"><label>1</label>Department of Neurology, Kennedy Krieger
Institute, Baltimore, MD, USA</aff>
<aff id="aff2-2050313X18807622"><label>2</label>Department of Neurology, School of
Medicine, Johns Hopkins University, Baltimore, MD, USA</aff>
<aff id="aff3-2050313X18807622"><label>3</label>Department of Neurology, University
Medicine Greifswald, Greifswald, Germany</aff>
<aff id="aff4-2050313X18807622"><label>4</label>Hugo W. Moser Research Institute at
Kennedy Krieger, Kennedy Krieger Institute, Baltimore, MD, USA</aff>
<aff id="aff5-2050313X18807622"><label>5</label>Center for Neuroscience and Regenerative
Medicine, Uniformed Services University, Bethesda, MD, USA</aff>
<aff id="aff6-2050313X18807622"><label>6</label>Department of Anatomy, Physiology and
Genetics, School of Medicine, Uniformed Services University, Bethesda, MD, USA</aff>
<author-notes>
<corresp id="corresp1-2050313X18807622">Eboni I Lance, Department of Neurology,
Kennedy Krieger Institute, 801 North Broadway, Baltimore, MD 21205, USA. Email:
<email>lance@kennedykrieger.org</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>6</volume>
<elocation-id>2050313X18807622</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>9</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Â© The Author(s) 2018</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
<license license-type="creative-commons" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Pathogenic variants in <italic>EEF1A2</italic>, a gene encoding a eukaryotic
translation elongation factor, have been previously reported in pediatric cases
of epileptic encephalopathy and intellectual disability. We report a case of a
17-year-old male with a prior history of epilepsy, autism, intellectual
disability, and the abrupt onset of choreo-athetotic movements. The patient was
diagnosed with an <italic>EEF1A2</italic> variant by whole exome sequencing. His
movement disorder responded dramatically to treatment with tetrabenazine. To the
best of our knowledge, this is the first report of successful treatment of a
hyperkinetic movement disorder in the setting of <italic>EEF1A2</italic>
mutation. A trial with tetrabenazine should be considered in cases with
significant choreoathetosis.</p>
</abstract>
<kwd-group>
<kwd>Epilepsy</kwd>
<kwd>genetics</kwd>
<kwd>autism</kwd>
<kwd>chorea</kwd>
<kwd>treatment</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January-December 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="section1-2050313X18807622" sec-type="intro">
<title>Introduction</title>
<p>De novo variants in <italic>EEF1A2</italic> are associated with early infantile
epileptic encephalopathy 33 (MIM# 616409) and autosomal dominant intellectual
disability 38 (MIM# 616393). A de novo <italic>EEF1A2</italic> variant, p.G70S, was
initially reported by De Light et al.<sup><xref ref-type="bibr" rid="bibr1-2050313X18807622">1</xref></sup> in a female with epileptic encephalopathy. Subsequently, 16 additional
patients have been described in the published literature with 10 different de novo
variants. Consistent clinical features include epilepsy/epileptic encephalopathy and
global developmental delay/intellectual disability of varying severity (see <xref ref-type="table" rid="table1-2050313X18807622">Table 1</xref>). Autism or
autistic features, behavioral abnormalities such as stereotypies or self-injurious
behaviors, cerebral atrophy, microcephaly, and facial dysmorphism have also been
reported in some patients. A recent conference report described abnormal movements
in 14 patients with de novo variants in <italic>EEF1A2</italic>.<sup><xref ref-type="bibr" rid="bibr9-2050313X18807622">9</xref></sup> Patients were noted to have focal or generalized epilepsy, chorea and/or
dystonia, and developmental encephalopathy with neuroimaging features of global
cortical volume loss and hypomyelination.</p>
<table-wrap id="table1-2050313X18807622" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>Summary of cases.</p>
</caption>
<alternatives>
<graphic xlink:href="10.1177_2050313X18807622-table1"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">References</th>
<th align="left" colspan="1" rowspan="1">De Ligt<sup><xref ref-type="bibr" rid="bibr1-2050313X18807622">1</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Veeramah et al.<sup><xref ref-type="bibr" rid="bibr2-2050313X18807622">2</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Nakajima et al.<sup><xref ref-type="bibr" rid="bibr3-2050313X18807622">3</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Nakajima et al.<sup><xref ref-type="bibr" rid="bibr3-2050313X18807622">3</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Lopes et al.<sup><xref ref-type="bibr" rid="bibr4-2050313X18807622">4</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Lam et al.<sup><xref ref-type="bibr" rid="bibr5-2050313X18807622">5</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Lam et al.<sup><xref ref-type="bibr" rid="bibr5-2050313X18807622">5</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Lam et al.<sup><xref ref-type="bibr" rid="bibr5-2050313X18807622">5</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Lam et al.<sup><xref ref-type="bibr" rid="bibr5-2050313X18807622">5</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Lam et al.<sup><xref ref-type="bibr" rid="bibr5-2050313X18807622">5</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Lam et al.<sup><xref ref-type="bibr" rid="bibr5-2050313X18807622">5</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Lam et al.<sup><xref ref-type="bibr" rid="bibr5-2050313X18807622">5</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Inui et al.<sup><xref ref-type="bibr" rid="bibr6-2050313X18807622">6</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Inui et al.<sup><xref ref-type="bibr" rid="bibr6-2050313X18807622">6</xref></sup></th>
<th align="left" colspan="1" rowspan="1">De Kovel et al.<sup><xref ref-type="bibr" rid="bibr7-2050313X18807622">7</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Helbig et al.<sup><xref ref-type="bibr" rid="bibr8-2050313X18807622">8</xref></sup></th>
<th align="left" colspan="1" rowspan="1">Helbig et al.<sup><xref ref-type="bibr" rid="bibr8-2050313X18807622">8</xref></sup></th>
<th align="left" colspan="1" rowspan="1">This Report</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Patient#</td>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">4</td>
<td colspan="1" rowspan="1">5</td>
<td colspan="1" rowspan="1">6</td>
<td colspan="1" rowspan="1">7</td>
<td colspan="1" rowspan="1">8</td>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1">10</td>
<td colspan="1" rowspan="1">11</td>
<td colspan="1" rowspan="1">12</td>
<td colspan="1" rowspan="1">13</td>
<td colspan="1" rowspan="1">14</td>
<td colspan="1" rowspan="1">15</td>
<td colspan="1" rowspan="1">16</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1">18</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Mutation</td>
<td colspan="1" rowspan="1">G70S</td>
<td colspan="1" rowspan="1">G70S</td>
<td colspan="1" rowspan="1">D252H</td>
<td colspan="1" rowspan="1">E122K</td>
<td colspan="1" rowspan="1">A92T</td>
<td colspan="1" rowspan="1">G70S</td>
<td colspan="1" rowspan="1">I71L</td>
<td colspan="1" rowspan="1">D91N</td>
<td colspan="1" rowspan="1">F98L</td>
<td colspan="1" rowspan="1">E122K</td>
<td colspan="1" rowspan="1">E124K</td>
<td colspan="1" rowspan="1">R423C</td>
<td colspan="1" rowspan="1">E122K</td>
<td colspan="1" rowspan="1">E122K</td>
<td colspan="1" rowspan="1">G70S</td>
<td colspan="1" rowspan="1">G70S</td>
<td colspan="1" rowspan="1">R266W</td>
<td colspan="1" rowspan="1">L246P</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GDD/ID</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Hypotonia</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Autism/autistic features</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Behavior abnormalities</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Abnormal movements</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ataxia/unstable gait</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Microcephaly</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">â</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Epilepsy</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Facial dysmorphism</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">â</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">nr</td>
<td colspan="1" rowspan="1">+</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="table-fn1-2050313X18807622">
<p>nr: not reported; GDD: global developmental delay; ID: intellectual
disability.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section2-2050313X18807622">
<title>Case</title>
<p>The patient is a 17-year-old male born at term following a pregnancy complicated by
maternal alcohol and substance abuse. Development was delayed: he walked at age
18âmonths, requiring braces for support, and his first words were at age 4âyears.
Medical history includes strabismus status post surgery at age 1âyear,
hypothyroidism, asthma, gastroesophageal reflux disease, kidney dysfunction,
ischemic stroke, and epilepsy well controlled on valproic acid. The patient had an
episode of dystonia associated with anti-psychotic treatment (haloperidol,
aripiprazole) for bipolar disorder and aggression at age 9. Limited medical record
documentation exists regarding the history of ischemic stroke. Magnetic resonance
imaging (MRI) of the brain at ages 9 and 12 were normal. Family history is positive
for bipolar disorder in his mother. Paternal family history is unknown. The patient
has three healthy maternal half-siblings; ancestry is Caucasian.</p>
<p>He first presented to our institution at age 15âyears 6âmonths for management of his
seizures. The patient had a wide-based gait, balance impairment, and dysarthria. He
demonstrated developmental skills at the 3- to 5-year level. At 2âmonths after his
initial evaluation, he had the abrupt onset of severe choreo-athetotic movements
affecting his face, arms, and trunk (see <ext-link ext-link-type="uri" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/2050313X18807622">Supplemental Video</ext-link>). These movements dramatically affected his gait
and resulted in use of a wheelchair. His speech, behavior, and short-term memory
worsened as well. There was no acute preceding event or change of medication
(benztropine 1âmg twice daily, valproic acid 500âmg twice daily, dextroamphetamine
5âmg once daily, diphenhydramine 50âmg every 6âh as needed, levothyroxine 31.25âmcg
once daily, fluoxetine 20âmg once daily). Shortly thereafter, the patient was
admitted twice to a psychiatric hospital because of anger issues and aggression, but
did not require change of medication. He had another seizure after his 16th birthday
and a third brain MRI was normal. Over the next several months, his condition
worsened due to the involuntary movements and he was no longer able to feed or bathe
himself. Gastrostomy (G) tube feeding was required for caloric support. His
hyperkinetic movements failed to respond to benztropine 1âmg BID and valproic acid
500âmg BID.</p>
<p>Evaluation in a Pediatric Movement Disorders clinic at age 16âyears and 4âmonths
showed continuous choreo-athetotic movements of his face, trunk, and extremities. A
trial with tetrabenazine (TBZ) 12.5âmg BID was initiated, which markedly improved
his involuntary movements within 2âweeks. At his most recent follow-up visit (age
17âyears), he was able to walk, feed himself, and use the bathroom independently. He
continued to have antecollis and difficulties with gait, balance, and dysarthria,
but was close to his baseline presentation.</p>
<p>Additional neurodiagnostic testing included a normal (fourth) brain MRI,
single-nucleotide polymorphism (SNP) chromosomal array, Fragile X DNA testing, and
mitochondrial DNA sequencing and deletion/duplication testing. A fasting lumbar
puncture revealed a slightly low cerebrospinal fluid (CSF) glucose of 48âmg/dL
(normal range 50â75); however, plasma-to-CSF glucose ratio (0.56) was not suggestive
of GLUT1 deficiency. CSF lactate, pyridoxal phosphate, neurotransmitter metabolites,
tetrahydrobiopterin, neopterin, 5-methyltetrahydrofolate, and succinyladenosine were
all normal. CSF amino acids did not identify any abnormalities consistent with a
metabolic disorder. Plasma amino acids showed elevated alanine and glycine, but were
normal on repeat testing. Lactate, pyruvate, and urine organic acids were normal. In
light of extensive negative work-up, whole exome sequencing was performed using the
methods previously described.<sup><xref ref-type="bibr" rid="bibr10-2050313X18807622">10</xref></sup></p>
<p>Results identified a heterozygous missense variant, c.737T&gt;C (p.L246P) in the
<italic>EEF1A2</italic> gene (NM_001958.3). Targeted testing of the patientâs
maternal grandmother was negative; biological parental samples were not available to
confirm a de novo occurrence in the patient.</p>
</sec>
<sec id="section3-2050313X18807622" sec-type="discussion">
<title>Discussion</title>
<p>The defined EEF1A2 abnormalities in this patient have not been previously reported in
affected individuals, and it is absent from 138,632 exome/genome sequences in the
Genome Aggregation Database (<ext-link ext-link-type="uri" xlink:href="http://gnomad.broadinstitute.org/">http://gnomad.broadinstitute.org/</ext-link>). The p.L246P variant is a
semi-conservative amino acid substitution that occurs at a position that is
evolutionarily conserved across species, and in silico analysis predicts that this
alteration is likely damaging to protein structure/function.<sup><xref ref-type="bibr" rid="bibr11-2050313X18807622">11</xref></sup> It is located in domain II of the protein, which is involved in the binding
of aminoacyl-tRNA. Pathogenic variants have been documented at nearby residues (e.g. p.D252H),<sup><xref ref-type="bibr" rid="bibr3-2050313X18807622">3</xref></sup> supporting the functional importance of this region. We interpret this
variant to be causative of the patientâs neurodevelopmental impairments, epilepsy,
facial dysmorphism, and movement disorder.</p>
<p>The <italic>EEF1A2</italic> gene encodes the eukaryotic translation elongation
factor-1, alpha-2, which is critical for the GTP-dependent binding of
aminoacyl-tRNAs to the ribosome during protein synthesis.<sup><xref ref-type="bibr" rid="bibr12-2050313X18807622">12</xref></sup> The genes which encode the two eEF1A isoforms are expressed ubiquitously
during early development, but <italic>EEF1A1</italic> and <italic>EEF1A2</italic>
are expressed in mutually exclusive somatic patterns around the time of weaning in
juvenile mice. Complete homozygous loss of <italic>EEF1A2</italic> expression in
mice gives rise to the âwastedâ phenotype, in which the affected mice exhibit motor
neuron disease with concomitant skeletal muscle atrophy leading to morbidity
requiring euthanasia within 1âmonth of life.<sup><xref ref-type="bibr" rid="bibr13-2050313X18807622">13</xref></sup></p>
<p>A recent article showed that the human pathogenic p.G70S eEF1A2 variant, introduced
into mice via CRISPR mutagenesis, mimicked the wasted phenotype with the addition of
a fatal audiogenic seizure phenotype.<sup><xref ref-type="bibr" rid="bibr14-2050313X18807622">14</xref></sup> Furthermore, a mouse model which carried two copies of p.G70S exhibited an
accelerated wasting phenotype requiring euthanasia at 18âdays old. These data
suggest that the p.G70S variant might confer a pathologic gain of function in
addition to its loss of protein translation function. Nevertheless, it is recognized
that the p.G70S mutation is in a physically and functionally remote location on the
eEF1A2 protein relative to the p.L246P mutation identified in our patient. It
remains unclear whether the neuropathologic phenotypes are a general consequence of
human <italic>EEF1A2</italic> loss-of-function variants or correlate to mutations in
distinct regions of the eEF1A2 protein.</p>
</sec>
<sec id="section4-2050313X18807622" sec-type="conclusions">
<title>Conclusion</title>
<p>Movement abnormalities associated with variants in <italic>EEF1A2</italic> are
variable, including chorea, dystonia, unsteady gait, and/or ataxia. Our patient had
an early history of ill-defined involuntary movements. Transient dystonic movements
were reported with use of dopamine antagonists (age 9), and 6âyears later he
developed severe choreo-athetotic movements. The latter movements, we believe, are
attributed to his underlying genetic mutation, although it is recognized that
fluoxetine is associated with hyperkinesia in about 2% of children and adolescents
and the patient has preceding history of prenatal drug exposure and reportedly a
prior ischemic stroke. As described, his hyperkinetic movements dramatically
responded to TBZ. TBZ depletes dopamine by inhibiting the vesicular monoamine
transport of this neurotransmitter. TBZ is approved by the US Food and Drug
Administration for treatment of chorea associated with Huntington disease; however,
it has been shown to be effective for a large variety of hyperkinetic disorders.<sup><xref ref-type="bibr" rid="bibr15-2050313X18807622">15</xref></sup> Practitioners must also consider the potential adverse central nervous system
effects of TBZ that might be particularly concerning in patients with epileptic
encephalopathy, specifically fatigue, sedation, depression, and falling. Based on
this report, a trial with TBZ should be considered in those individuals with
significant choreoathetosis and an <italic>EEF1A2</italic> mutation.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<caption>
<title>Supplemental Video</title>
</caption>
<media id="d35e878" mime-subtype="avi" mimetype="application" orientation="portrait" position="anchor" xlink:href="sj-vid-1-sco-10.1177_2050313X18807622.avi"></media>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="COI-statement">
<p><bold>Declaration of conflicting interests:</bold> J.S.C. is a consultant for Invitae. H.S.S. is a consultant for TEVA
pharmaceuticals. A.F. has received personal compensation in the form of
consultant fees from Aevi Genomic Medicine, Vertex Pharmaceuticals, Stealth
Biotherapeutics, BluebirdBio, and Calico Labs for services unrelated to the
reported topic. The other authors declare that they have no competing
interests.</p>
</fn>
<fn fn-type="other">
<p><bold>Ethical approval:</bold> Our institution does not require ethical approval for reporting individual cases
or case series.</p>
</fn>
<fn fn-type="financial-disclosure">
<p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or
publication of this article.</p>
</fn>
<fn fn-type="other">
<p><bold>Informed consent:</bold> Informed consent was obtained from the subjectâs legal guardian to publish this
case report and related video.</p>
</fn>
<fn fn-type="other">
<p><bold>ORCID iD:</bold> Eboni I Lance <inline-graphic xlink:href="10.1177_2050313X18807622-img1.jpg"></inline-graphic>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-7332-8777">https://orcid.org/0000-0001-7332-8777</ext-link></p>
</fn>
<fn fn-type="supplementary-material">
<p><bold>Supplemental material:</bold> Supplemental material is available for this article online.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2050313X18807622">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Light</surname><given-names>J</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>Van Bon</surname><given-names>BW</given-names></name><etal>et al</etal></person-group>
<article-title>Diagnostic exome sequencing in persons with
severe intellectual disability</article-title>. <source/>N Engl J
Med
<year>2012</year>; <volume>20</volume>:
<fpage>1921</fpage>â<lpage>1929</lpage>.</mixed-citation>
</ref>
<ref id="bibr2-2050313X18807622">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veeramah</surname><given-names>KR</given-names></name><name><surname>Johnstone</surname><given-names>L</given-names></name><name><surname>Karafet</surname><given-names>TM</given-names></name><etal>et al</etal></person-group>
<article-title>Exome sequencing reveals new causal mutations in
children with epileptic encephalopathies</article-title>.
<source/>Epilepsia
<year>2013</year>; <volume>7</volume>:
<fpage>1270</fpage>â<lpage>1281</lpage>.</mixed-citation>
</ref>
<ref id="bibr3-2050313X18807622">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>J</given-names></name><name><surname>Okamoto</surname><given-names>N</given-names></name><name><surname>Tohyama</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>De novo EEF1A2 mutations in patients with
characteristic facial features, intellectual disability, autistic behaviors
and epilepsy</article-title>. <source/>Clin Genet
<year>2015</year>; <volume>4</volume>:
<fpage>356</fpage>â<lpage>361</lpage>.</mixed-citation>
</ref>
<ref id="bibr4-2050313X18807622">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lopes</surname><given-names>F</given-names></name><name><surname>Barbosa</surname><given-names>M</given-names></name><name><surname>Ameur</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Identification of novel genetic causes of Rett
syndrome-like phenotypes</article-title>. <source/>J Med Genet
<year>2016</year>; <volume>3</volume>:
<fpage>190</fpage>â<lpage>199</lpage>.</mixed-citation>
</ref>
<ref id="bibr5-2050313X18807622">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lam</surname><given-names>WW</given-names></name><name><surname>Millichap</surname><given-names>JJ</given-names></name><name><surname>Soares</surname><given-names>DC</given-names></name><etal>et al</etal></person-group>
<article-title>Novel de novo EEF1A2 missense mutations causing
epilepsy and intellectual disability</article-title>. <source/>Mol Genet
Genomic Med
<year>2016</year>; <volume>4</volume>:
<fpage>465</fpage>â<lpage>474</lpage>.<pub-id pub-id-type="pmid">27441201</pub-id></mixed-citation>
</ref>
<ref id="bibr6-2050313X18807622">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Inui</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Ashikari</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>Two cases of early-onset myoclonic seizures with
continuous parietal delta activity caused by EEF1A2
mutations</article-title>. <source/>Brain Dev
<year>2016</year>; <volume>5</volume>:
<fpage>520</fpage>â<lpage>524</lpage>.</mixed-citation>
</ref>
<ref id="bibr7-2050313X18807622">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Kovel</surname><given-names>CG</given-names></name><name><surname>Brilstra</surname><given-names>EH</given-names></name><name><surname>van Kempen</surname><given-names>MJ</given-names></name><etal>et al</etal></person-group>
<article-title>Targeted sequencing of 351 candidate genes for
epileptic encephalopathy in a large cohort of patients</article-title>.
<source/>Mol Genet Genomic Med
<year>2016</year>; <volume>5</volume>:
<fpage>568</fpage>â<lpage>580</lpage>.</mixed-citation>
</ref>
<ref id="bibr8-2050313X18807622">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Helbig</surname><given-names>KL</given-names></name><name><surname>Farwell Hagman</surname><given-names>KD</given-names></name><name><surname>Shinde</surname><given-names>DN</given-names></name><etal>et al</etal></person-group>
<article-title>Diagnostic exome sequencing provides a molecular
diagnosis for a significant proportion of patients with
epilepsy</article-title>. <source/>Genet Med
<year>2016</year>; <volume>9</volume>:
<fpage>898</fpage>â<lpage>905</lpage>.</mixed-citation>
</ref>
<ref id="bibr9-2050313X18807622">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kruer</surname><given-names>M</given-names></name><name><surname>Padilla-Lopez</surname><given-names>S</given-names></name><name><surname>Helbig</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Heterozygous de novo mutations in EEF1A2 Lead to
an epileptic-dyskinetic encephalopathy</article-title>. <source/>Ann
Neurol
<year>2016</year>; <volume>20</volume>:
<fpage>S296</fpage>â<lpage>S297</lpage>.</mixed-citation>
</ref>
<ref id="bibr10-2050313X18807622">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Retterer</surname><given-names>K</given-names></name><name><surname>Juusola</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>MT</given-names></name><etal>et al</etal></person-group>
<article-title>Clinical application of whole-exome sequencing
across clinical indications</article-title>. <source/>Genet Med
<year>2016</year>; <volume>7</volume>:
<fpage>696</fpage>â<lpage>704</lpage>.</mixed-citation>
</ref>
<ref id="bibr11-2050313X18807622">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soares</surname><given-names>DC</given-names></name><name><surname>Barlow</surname><given-names>PN</given-names></name><name><surname>Newbery</surname><given-names>HJ</given-names></name><etal>et al</etal></person-group>
<article-title>Structural models of human eEF1A1 and eEF1A2
reveal two distinct surface clusters of sequence variation and potential
differences in phosphorylation</article-title>. <source/>PLoS ONE
<year>2009</year>; <volume>7</volume>: e6315.</mixed-citation>
</ref>
<ref id="bibr12-2050313X18807622">
<label>12</label>
<mixed-citation publication-type="gov">
<collab>NCBI Gene: EEF1A2 eukaryotic translation elongation factor 1 alpha 2
[Homo sapiens (human)]</collab>, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gene/1917#general-gene-info">https://www.ncbi.nlm.nih.gov/gene/1917#general-gene-info</ext-link>
(<year>2018</year>, <comment>accessed 9 March
2018</comment>).</mixed-citation>
</ref>
<ref id="bibr13-2050313X18807622">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chambers</surname><given-names>DM</given-names></name><name><surname>Peters</surname><given-names>J</given-names></name><name><surname>Abbott</surname><given-names>CM.</given-names></name></person-group>
<article-title>The lethal mutation of the mouse wasted (wst) is a deletion that
abolishes expression of a tissue-specific isoform of translation elongation
factor 1alpha, encoded by the Eef1a2 gene</article-title>. <source/>Proc Natl
Acad Sci U S A
<year>1998</year>; <volume>8</volume>:
<fpage>4463</fpage>â<lpage>4468</lpage>.</mixed-citation>
</ref>
<ref id="bibr14-2050313X18807622">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davies</surname><given-names>FC</given-names></name><name><surname>Hope</surname><given-names>JE</given-names></name><name><surname>McLachlan</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Biallelic mutations in the gene encoding eEF1A2
cause seizures and sudden death in F0 mice</article-title>. <source/>Sci
Rep
<year>2017</year>; <volume>7</volume>: 46019.</mixed-citation>
</ref>
<ref id="bibr15-2050313X18807622">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jankovic</surname><given-names>J.</given-names></name></person-group>
<article-title>Dopamine depleters in the treatment of hyperkinetic movement
disorders</article-title>. <source/>Expert Opin Pharmacother
<year>2016</year>; <volume>18</volume>:
<fpage>2461</fpage>â<lpage>2470</lpage>.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>